In vitro inhibitory activity of boropinic acid against Helicobacter pylori

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 21, 2006, Pages 5523-5525

  Epifano, Francesco ^a   Menghini, Luigi ^a   Pagiotti, Rita ^b   Angelini, Paola ^b   Genovese, Salvatore ^c   Curini, Massimo ^c  

^a Dipartimento di Scienze del Farmaco   (Italy)

^b Dipartimento di Biologia Vegetale e Biotecnologie Agrombientali   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Boropinic acid; Helicobacter pylori; Prenyloxy phenylpropanoids

Indexed keywords

AMOXICILLIN; AURAPTENE; BOROPINIC ACID; CLARITHROMYCIN; COUMARIN DERIVATIVE; METRONIDAZOLE; PLANT MEDICINAL PRODUCT; TETRACYCLINE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; BORRONIA PINNATA; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; HELICOBACTER PYLORI; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RUTACEAE;

CARBOXYLIC ACIDS; HELICOBACTER PYLORI; RUTACEAE;

BORONIA; HELICOBACTER PYLORI; RUTACEAE;

EID: 33748775250     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.08.043     Document Type: Article

References (15)

1. Dunn B.E., Cohen H., and Blase M.J. Clin. Microbiol. Rev. 10 (1997) 720
2. Lee J.H., Shim J.S., Lee J.S., Kim M.K., Chung M.S., and Kim H.K. Carbohydr. Res. 341 (2006) 1154
3. Graham D.Y., Lew G.M., and Klein P.D. Ann. Int. Med. 116 (1992) 705
4. Sorberg M.H., Hanberger H., Nilsson M., Bjorkman A., and Nilsson L.E. Antimicrob. Agents Chemother. 42 (1998) 1222
5. Curini M., Epifano F., and Genovese G. Bioorg. Med. Chem. Lett. 15 (2005) 5049 and references cited herein
6. Curini M., Cravotto G., Epifano F., and Giannone G. Curr. Med. Chem. 13 (2006) 199
7. Prager R.H., and Thregold H.M. Aust. J. Chem. 19 (1966) 451
8. Ito C., Itoigawa M., Otsuka T., Tokuda H., Nishino H., and Furukawa H. J. Nat. Prod. 63 (2000) 1344
9. Ali M.S., and Pervez M.K. Nat. Prod. Res. 18 (2004) 141
10. Perry N.B., Foster L.M., Lorimer S.D., May B.C., and Weavers R.T. J. Nat. Prod. 59 (1996) 729
11. 7 CFU/mL) and incubated at 37 °C for 3 days under microaerobic conditions. An antimicrobic-free plate and plates with corresponding dilutions of DMSO were used as negative controls to ensure bacterial viability and no contaminants in inoculums.
12. Curini M., Epifano F., Maltese F., Prieto Gonzales S.P., and Rodriguez J.C. Aust. J. Chem. 59 (2003) 59
13. National Committee for Clinical Laboratory Standards, Performance standards for antimicrobial susceptibility testing. V informational supplement. M100S9 National Committee for Clinical Laboratory Standards, Villanova, PA.
14. Chimenti F., Bizzarri B., Bolasco A., Secci D., Cimenti P., and Carradori S. Eur. J. Med. Chem. 41 (2006) 208
15. Takemura Y., Kawaguchi H., Maki S., Juichi M., Omura M., Ito C., and Furukawa H. Chem. Pharm. Bull 44 (1996) 804